Patent · US Active

Oligonucleotide targeted to the A20-3′ untranslated region

US10731163B2 · kind B2 · utility

0Cited by

5References

11Claims

0Family size

Assignee

Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft · DE

Inventors

Markus Landthaler · Berlin, DE
Yasuhiro Murakawa · Saitama, JP

Key dates

Filing date	Sep 2, 2015
Grant date	Aug 4, 2020
Priority date	—
Expiry date	Sep 2, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/3231
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

An antisense oligonucleotide comprising a sequence targeted to the 3′ untranslated region (3′ UTR) of the TNFAIP3 (A20) transcript and its use as a medicament, for example in the treatment of cancer or an autoimmune disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.